Načítá se...
Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20(+) B Cell Malignancies
We previously reported a 24% 1-year relapse rate in 93 older or medically unfit patients with CD20(+) B cell malignancies after allogeneic hematopoietic cell transplantation (HCT) with low-intensity conditioning. The current prospective study tested the hypothesis that disease relapse could be reduc...
Uloženo v:
| Vydáno v: | Biol Blood Marrow Transplant |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7549403/ https://ncbi.nlm.nih.gov/pubmed/32693210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.014 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|